A number of other equities research analysts have also recently weighed in on AKBA. JPMorgan Chase & Co. set a €28.20 ($32.79) price objective on shares of AXA and gave the company a buy rating in a research note on Thursday, May 2nd. Citigroup started coverage on shares of Akebia Therapeutics in a research note on Wednesday, March 20th. They set a neutral rating and a $9.00 price objective on the stock. Finally, ValuEngine upgraded shares of China Southern Airlines from a sell rating to a hold rating in a research note on Tuesday, June 11th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the stock. The company has a consensus rating of Hold and an average price target of $13.92.
Akebia Therapeutics stock opened at $4.22 on Tuesday. The firm has a market capitalization of $504.45 million, a P/E ratio of -1.73 and a beta of 1.49. The stock has a fifty day simple moving average of $4.52. The company has a current ratio of 1.71, a quick ratio of 1.15 and a debt-to-equity ratio of 0.06. Akebia Therapeutics has a 12 month low of $4.08 and a 12 month high of $10.73.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Clearbridge Investments LLC boosted its holdings in Akebia Therapeutics by 3.4% in the first quarter. Clearbridge Investments LLC now owns 1,257,336 shares of the biopharmaceutical company’s stock valued at $10,298,000 after acquiring an additional 41,450 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in shares of Akebia Therapeutics in the 1st quarter valued at about $160,000. Lido Advisors LLC lifted its stake in shares of Akebia Therapeutics by 26.5% in the 1st quarter. Lido Advisors LLC now owns 47,686 shares of the biopharmaceutical company’s stock valued at $390,000 after purchasing an additional 9,986 shares during the period. DekaBank Deutsche Girozentrale lifted its stake in shares of Akebia Therapeutics by 20.5% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 20,600 shares of the biopharmaceutical company’s stock valued at $170,000 after purchasing an additional 3,500 shares during the period. Finally, IndexIQ Advisors LLC acquired a new position in shares of Akebia Therapeutics in the 1st quarter valued at about $1,522,000. Institutional investors and hedge funds own 70.50% of the company’s stock.
About Akebia Therapeutics
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients.
Further Reading: Trading Strategy Methods for Individual Investors
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.